William Blair Has Positive Outlook for APLS Q3 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at William Blair raised their Q3 2025 earnings estimates for Apellis Pharmaceuticals in a report issued on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn ($0.15) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.73) EPS and Q1 2026 earnings at $0.02 EPS.

A number of other brokerages also recently weighed in on APLS. HC Wainwright reiterated a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Scotiabank raised their price target on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a report on Wednesday. Wedbush decreased their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. JPMorgan Chase & Co. increased their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada decreased their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.59.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $19.97 on Friday. The stock has a market capitalization of $2.51 billion, a PE ratio of -9.84 and a beta of 0.85. The business’s 50 day simple moving average is $26.22 and its 200 day simple moving average is $29.00. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals has a one year low of $19.76 and a one year high of $57.85.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. The company had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.73) earnings per share.

Insider Activity

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 13,551 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $412,356.93. Following the completion of the sale, the chief executive officer now owns 418,519 shares in the company, valued at approximately $12,735,533.17. The trade was a 3.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the transaction, the chief accounting officer now owns 48,138 shares in the company, valued at approximately $1,464,839.34. This represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,054 shares of company stock worth $1,952,719. 6.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC boosted its stake in Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares in the last quarter. Signaturefd LLC increased its stake in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after purchasing an additional 918 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Apellis Pharmaceuticals in the 4th quarter worth approximately $83,000. US Bancorp DE raised its stake in Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after buying an additional 1,327 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in Apellis Pharmaceuticals by 1,819.2% in the fourth quarter. Covestor Ltd now owns 3,992 shares of the company’s stock worth $127,000 after acquiring an additional 3,784 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).